Literature DB >> 21127878

Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice.

Chunyan He1, Xuehong Lu, Zhaowei Yan, Man Wu, Shujun Liu, Yongli Yu, Ping Luo.   

Abstract

Mice with chronic graft-versus-host disease (cGVHD) induced by transferring parental BALB/C lymphocytes into (C57BL/6 × BALB/C) F1 (CBF1) hybrids, develop a syndrome characterized by B-cell hyperactivity, autoantibody production, and immune complex-mediated glomerulonephritis. In this model, we evaluated the role of leflunomide on the development of lupus nephritis in system autoimmunity. Daily administration of leflunomide (15 mg/kg/d) from 2 weeks after cGVHD induction can dramatically reduce the production of autoantibodies and immune complex deposition in the kidney, leading to relieved kidney damage and reduced mortality. The therapeutic effect of leflunomide on the lupus-prone mice was partially due to the inhibition of TLR9 signaling pathway, which was an important component of innate immune system.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21127878     DOI： 10.1007/s00296-010-1630-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  29 in total

1.  Somatically mutated IgG anti-DNA antibody clonally related to germ-line encoded IgM anti-DNA antibody.

Authors:  S Taki; S Hirose; K Kinoshita; H Nishimura; T Shimamura; J Hamuro; T Shirai
Journal:  Eur J Immunol       Date:  1992-04       Impact factor: 5.532

2.  The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation.

Authors:  H Bootsma; P E Spronk; E J Ter Borg; E J Hummel; G de Boer; P C Limburg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

Review 3.  Toll-like receptors, endogenous ligands, and systemic autoimmune disease.

Authors:  Ian R Rifkin; Elizabeth A Leadbetter; Liliana Busconi; Gregory Viglianti; Ann Marshak-Rothstein
Journal:  Immunol Rev       Date:  2005-04       Impact factor: 12.988

Review 4.  T- and B-cell abnormalities in systemic lupus erythematosus.

Authors:  Gyorgy Nagy; Agnes Koncz; Andras Perl
Journal:  Crit Rev Immunol       Date:  2005       Impact factor: 2.214

5.  Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.

Authors:  Terry K Means; Eicke Latz; Fumitaka Hayashi; Mandakolathur R Murali; Douglas T Golenbock; Andrew D Luster
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

6.  Suppression of experimental autoimmune neuritis by leflunomide.

Authors:  T Korn; K Toyka; H P Hartung; S Jung
Journal:  Brain       Date:  2001-09       Impact factor: 13.501

7.  In vitro autoantibody production by normal adult and cord blood B cells.

Authors:  D S Pisetsky; D F Jelinek; L M McAnally; C F Reich; P E Lipsky
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

8.  Relationship of renal histopathology in SLE nephritis to immunoglobulin class of anti-DNA.

Authors:  J D Clough; R Valenzuela
Journal:  Am J Med       Date:  1980-01       Impact factor: 4.965

9.  Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis.

Authors:  F Förger; T Matthias; M Oppermann; H Becker; K Helmke
Journal:  Lupus       Date:  2004       Impact factor: 2.911

10.  The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy.

Authors:  F S Zhang; Y K Nie; X M Jin; H M Yu; Y N Li; Y Sun
Journal:  Rheumatol Int       Date:  2009-01-25       Impact factor: 2.631
View more
  5 in total

1.  The effects of leflunomide on CD4(+)CD25 (+)Foxp3 (+) T regulatory cells in mice receiving allogeneic bone marrow transplantation.

Authors:  Di Jin; Kaizhong Duan; Lianjun Zhang; Jianxia Peng; Yong Zhao
Journal:  Inflamm Res       Date:  2011-11-05       Impact factor: 4.575

Review 2.  Leflunomide: friend or foe for systemic lupus erythematosus?

Authors:  Guo-Cui Wu; Xiao-Di Xu; Qiong Huang; Hua Wu
Journal:  Rheumatol Int       Date:  2012-09-08       Impact factor: 2.631

3.  Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats.

Authors:  Cheng-bo Fang; De-xi Zhou; Shu-xiang Zhan; Yong He; Zhen Lin; Cheng Huang; Jun Li
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

Review 4.  The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis.

Authors:  Heng Cao; Yuefeng Rao; Lin Liu; Jin Lin; Hongyu Yang; Xingguo Zhang; Zhong Chen
Journal:  PLoS One       Date:  2015-12-15       Impact factor: 3.240

5.  Leflunomide-Induced Hidradenitis Suppurativa.

Authors:  Achraf Machan; Hasna Azendour; Hamza Toufik; Lahsen Achemlal; Mohammed Boui; Naoufal Hjira
Journal:  Case Rep Rheumatol       Date:  2020-02-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.